Latest Forum Topics /
IX Biopharma
Last:0.355
+0.01
|
 Post Reply
|
|
iX Biopharma
|
|||||
|
Barcalo
Master |
11-Feb-2026 16:22
|
||||
|
x 0
x 0 Alert Admin |
Halted 2 days or more maybe due to questioning from SGX regarding their irregular trading push.
|
||||
| Useful To Me Not Useful To Me | |||||
|
stlimst
Master |
11-Feb-2026 15:50
|
||||
|
x 0
x 0 Alert Admin |
IX Biopharma will reward me handsomely for having the faith to support this pharma company. I already said, commerciialisation after clinical trial is the key to unlock the value. |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Stocky901
Supreme |
11-Feb-2026 15:48
|
||||
|
x 0
x 0 Alert Admin |
That means they have to do a very massive rights/warrants issues? 🤔
|
||||
| Useful To Me Not Useful To Me | |||||
|
Cadence88
Veteran |
11-Feb-2026 14:47
|
||||
|
x 0
x 0 Alert Admin |
For nasdaq dual lsiting , its amrket cap needs to be > = $2B, i think. | ||||
| Useful To Me Not Useful To Me | |||||
|
hschsc
Master |
11-Feb-2026 14:44
Yells: "Invest in financially healthy companies" |
||||
|
x 0
x 0 Alert Admin |
Still lose ,how to apply for second listing ? | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Stocky901
Supreme |
11-Feb-2026 13:37
|
||||
|
x 0
x 1 Alert Admin |
If dual listing news, reopening price should be above first ipo price (0.46)? Big angbao 🎁 🎁 | ||||
| Useful To Me Not Useful To Me | |||||
|
ahberngh
Elite |
11-Feb-2026 12:38
|
||||
|
x 0
x 1 Alert Admin |
Shortists watch out. If the hallt is over 2 to 3 days or more, then likely to be big news. Fingers crossed, get ready to cheong.
|
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
11-Feb-2026 12:35
|
||||
|
x 0
x 0 Alert Admin |
Halted | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
spursfan
Supreme |
11-Feb-2026 11:48
|
||||
|
x 0
x 2 Alert Admin |
you already posted it yesterday. too free? | ||||
| Useful To Me Not Useful To Me | |||||
|
Joelton
Supreme |
11-Feb-2026 11:46
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma reports lower net loss for 1HFY2026 iX Biopharma (SGX:42C) has posted a lower loss attributable to shareholders of the company of $2.06 million for 1HFY2026 ended Dec 31, 2025, an improvement of 67% y-o-y from $6.25 million on back of favourable exchange rate. Loss per share for 1HFY2026 was down to 0.23 cents, compared to 0.72 cents in 1HFY2025. Revenue declined 14% y-o-y to $3.18 million, mainly due to a lower revenue contribution from its medicinal cannabis manufacturing services provided to third parties. &ldquo This decline was caused mainly by delays faced by the Group&rsquo s customers in securing import clearances for raw materials, which constrained their demand for the Group&rsquo s manufacturing services,&rdquo said iX Biopharma. Gross margin improved to 26% in 1HFY2026, up from 22% in 1HFY2025, driven by a more favourable sales mix and tighter cost management. Total assets rose to $15.9 million as at Dec 31, 2025, due to higher cash balances as a result of recent proceeds raised from the private placement and warrant exercises. Net cash used in operating activities amounted to $1.94 million for 1HFY2026, mainly due to lower receipt of R& D incentive, partially offset by tighter cost management and improved sales mix. &ldquo With improved liquidity, a restored net asset position and continued cost discipline, the Board believes the Group is better positioned to execute its commercialisation strategy,&rdquo said iX Biopharma. Shares in iX Biopharma was up 0.9 cents, or 4.71% higher at 20 cents on Feb 6. |
||||
| Useful To Me Not Useful To Me | |||||
|
Tracer63
Elite |
11-Feb-2026 08:16
|
||||
|
x 0
x 0 Alert Admin |
This one gonna fly today | ||||
| Useful To Me Not Useful To Me | |||||
|
ahberngh
Elite |
10-Feb-2026 17:04
|
||||
|
x 0
x 0 Alert Admin |
Depending on how the business pan out, this one could be massive. |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Tracer63
Elite |
10-Feb-2026 16:56
|
||||
|
x 0
x 0 Alert Admin |
Ride the horse!!!
|
||||
| Useful To Me Not Useful To Me | |||||
|
Tracer63
Elite |
10-Feb-2026 16:53
|
||||
|
x 0
x 1 Alert Admin |
Closing 0.23 | ||||
| Useful To Me Not Useful To Me | |||||
|
Tracer63
Elite |
10-Feb-2026 16:49
|
||||
|
x 0
x 0 Alert Admin |
215 wall breaking down | ||||
| Useful To Me Not Useful To Me | |||||
|
spursfan
Supreme |
10-Feb-2026 16:43
|
||||
|
x 0
x 0 Alert Admin |
happy for those who bought this stock above 20cts during early stage of covid. where it traded as high as 30+ cts . at one stage it seems like heavy loss for them when it drop as low as below 2cts |
||||
| Useful To Me Not Useful To Me | |||||
|
Tracer63
Elite |
10-Feb-2026 16:36
|
||||
|
x 0
x 0 Alert Admin |
0.215 resistance will break
|
||||
| Useful To Me Not Useful To Me | |||||
|
Tracer63
Elite |
10-Feb-2026 15:36
|
||||
|
x 0
x 0 Alert Admin |
Sg stocks surging before budget announcement on Thurs. | ||||
| Useful To Me Not Useful To Me | |||||
|
Tracer63
Elite |
10-Feb-2026 15:29
|
||||
|
x 0
x 0 Alert Admin |
Looks pretty strong buying, looking to break resistance at 0.215 | ||||
| Useful To Me Not Useful To Me | |||||
|
Joelton
Supreme |
10-Feb-2026 11:05
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma reports lower net loss for 1HFY2026 iX Biopharma (SGX:42C) has posted a lower loss attributable to shareholders of the company of $2.06 million for 1HFY2026 ended Dec 31, 2025, an improvement of 67% y-o-y from $6.25 million on back of favourable exchange rate. Loss per share for 1HFY2026 was down to 0.23 cents, compared to 0.72 cents in 1HFY2025. Revenue declined 14% y-o-y to $3.18 million, mainly due to a lower revenue contribution from its medicinal cannabis manufacturing services provided to third parties. &ldquo This decline was caused mainly by delays faced by the Group&rsquo s customers in securing import clearances for raw materials, which constrained their demand for the Group&rsquo s manufacturing services,&rdquo said iX Biopharma. Gross margin improved to 26% in 1HFY2026, up from 22% in 1HFY2025, driven by a more favourable sales mix and tighter cost management. Total assets rose to $15.9 million as at Dec 31, 2025, due to higher cash balances as a result of recent proceeds raised from the private placement and warrant exercises. Net cash used in operating activities amounted to $1.94 million for 1HFY2026, mainly due to lower receipt of R& D incentive, partially offset by tighter cost management and improved sales mix. &ldquo With improved liquidity, a restored net asset position and continued cost discipline, the Board believes the Group is better positioned to execute its commercialisation strategy,&rdquo said iX Biopharma. Shares in iX Biopharma was up 0.9 cents, or 4.71% higher at 20 cents on Feb 6. |
||||
| Useful To Me Not Useful To Me | |||||